Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 7/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.70 |
| ▸ | HTR1D | P28221 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | HTR1B | P28222 | 2/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573946 | 0.91 | TRPM8 (0.69) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL853652 | 0.89 | TRPM8 (0.67) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL4490807 | 0.88 | PPARG (0.71) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL6388022 | 0.86 | POLB (0.78) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL28829276 | 0.86 | HTR1D (0.60) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL19051463 | 0.85 | TRPM8 (0.68) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL6988545 | 0.84 | HTR1D (0.78) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| 5-Benzyloxytryptamine SCHEMBL29785061 | 0.84 | TRPM8 (1.00) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL27406721 | 0.84 | TRPM8 (0.77) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL959573 | 0.84 | TRPM8 (0.77) | TRPM8KDM4EMAPTLTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425010-B8 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | JANSSEN PHARMACEUTICALS INC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1425010-A4 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1425010-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1423363-A1 | ORAL ANTIDIABETIC AGENTS | Warner-Lambert Company LLC (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002060438-A1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-0861248-B1 | INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | AMERICAN HOME PROD (US) | 2001-12-12 | — | — | EP | disclosed |
| CN-1205700-A | Indolylalkyl derivatives of benzodioxan methylamines as 5-HTiA receptor ligands | AMERICAN HOME PROD (US) | 1999-01-20 | — | — | CN | disclosed |
| EP-0861248-A1 | INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5750724-A | SEROTONIN 5-HT REUPTAKE INHIBITORS; ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997017343-A1 | INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | TRPM8 1323/4885KDM4E 1575/4885MAPT 3128/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | TRPM8 734/4885KDM4E 1764/4885MAPT 2981/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | TRPM8 673/4885KDM4E 1966/4885MAPT 3489/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | TRPM8 702/4885KDM4E 1782/4885MAPT 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.